SUFFOLK, United Kingdom, July 14, 2003 (PRIMEZONE) -- Celsis International plc, a world leading rapid microbial testing company whose diagnostic systems detect and measure contamination for the pharmaceutical, personal care, dairy and beverage industries, announces it has agreed a preferred supplier contract with GlaxoSmithKline (NYSE:GSK) for rapid microbial testing systems. Celsis have already implemented six systems in GlaxoSmithKline sites.
The Celsis rapid testing system provides product screening results in as little as 24 hours, enabling potential microbial quality problems to be detected sooner as well as reducing product release times compared to other more traditional screening methods. The net result to Celsis customers is significant financial savings through reduced inventory and warehousing costs.
Jay LeCoque, Chief Executive of Celsis stated:
"We are delighted to have secured this agreement with GlaxoSmithKline, a major global pharmaceutical company, and believe it highlights two things: 1) the increasing global acceptance of Celsis technology among the major pharmaceutical companies demonstrating that our years of regulatory partnerships are starting to show returns, and 2) the continued progress Celsis is making with the Global Corporate Account Management (GCAM) programme in implementing Celsis technology not just in the UK or the US, but anywhere our customers have a manufacturing or R&D facility in the world."
Celsis International plc Tel: 01638 600151 Jay LeCoque, Chief Executive Officer Jenny Parsons, Corporate Communications College Hill Tel: 020 7457 2020 Nicholas Nelson
Notes to editors
Celsis International plc
Celsis International plc is a world leader in the development and supply of rapid diagnostic and monitoring systems to detect and measure microbial contamination in finished products bound for consumers. It has successfully developed tests for use in the pharmaceutical, cosmetic and toiletries, food and beverage industries and is associated with some of the best-known high street brands in these consumer areas.
These tests are based upon the years of research in enzyme technology that employ numerous methods for the rapid detection of microbial contamination. The result is that microbial testing times are reduced from around five days to a little over one day, thus lending significant cost advantages to Celsis' customers.
Celsis International plc also has a leading cGMP laboratory services, supporting the R&D and manufacturing based testing needs of the pharmaceutical, biotechnology and personal care industries. This business unit currently operates primarily in the United States.
For more information on Celsis International plc go to www.celsis.com